Multiferon is now approved in Chile for the second-line treatment of any and all diseases in which recombinant interferon therapy failed, possibly due to the formation of neutralizing antibodies. As an alternative to single- subtype, recombinant alpha interferons, Multiferon is primarily marketed for the treatment of hepatitis B, hepatitis C, chronic myelogenous leukemia, hairy cell leukemia, renal cell carcinoma and malignant melanoma.
Viragen’s president and CEO, Charles Rice, stated, “We are pleased to announce achievement of yet another key milestone this year as we continue to meet our stated goals.
“As part of our South American strategy, Chile will be the first in this region to contribute to our sales growth, and with new approvals pending in other international markets, we are working towards building a global franchise to make Multiferon the most widely prescribed natural human alpha interferon in the world.”